CEO Executive AssistantCell and gene therapy CEOs operate inside one of the most demanding leadership environments in all of life sciences. The product is often a single-dose, potentially curative treatment. Manufacturing is biologics-level complex. The regulatory path requires deep engagement with FDA on chemistry, manufacturing, and controls (CMC) in addition to clinical strategy. Patients are waiting with no other options. And investors are watching every milestone with unusual intensity.
Time management for cell and gene therapy CEOs is not simply about efficiency. It is about correctly sequencing where executive attention lands across manufacturing scale-up, regulatory engagement, hospital system relationships, reimbursement architecture, and the scientific credibility that underlies all of it. Get that sequencing wrong and a company that has a genuinely transformative therapy can still fail to bring it to patients.
This article examines how the most effective cell and gene therapy CEOs structure their time, where they invest their personal attention, and where they rely on strong teams and systems to protect that investment.
The Manufacturing Problem That Consumes CEO Bandwidth
Why CMC Is a CEO-Level Problem
In traditional small-molecule pharma, manufacturing is largely an operations and quality function. The CEO is informed of issues but rarely needs to engage at a technical level. In cell and gene therapy, this dynamic is fundamentally different.
CMC is consistently one of the top FDA concerns in IND and BLA reviews for cell and gene therapy products. Manufacturing processes that are not well-characterized, reproducible, or scalable create regulatory risk that can delay or derail an otherwise strong clinical program. The FDA’s own guidance documents on gene therapy CMC considerations make clear that manufacturing process changes late in development carry significant regulatory consequence.
This means that cell and gene therapy CEOs need to maintain working fluency in CMC strategy even when they are not scientists. They need to understand when a process change is a standard optimization versus a comparability risk. They need to make resource decisions about viral vector manufacturing capacity, whether in-house or through CDMOs, years before commercial launch. And they need to hold their VP of Technical Operations accountable in ways that require genuine domain knowledge.
Structuring Manufacturing Oversight Without Getting Pulled Into Operations
The practical challenge is that manufacturing oversight can easily consume a disproportionate share of CEO time, especially during scale-up phases. A cell therapy manufacturing site running a Phase 2 or Phase 3 campaign will surface problems continuously. Equipment qualification failures, batch failures, out-of-specification results, staffing shortfalls at the site level: all of these will escalate if there is not a strong operations leader absorbing them.
Effective cell and gene therapy CEOs establish a clear escalation framework. Routine manufacturing decisions, including batch dispositions, minor process deviations, and equipment maintenance schedules, belong to the VP of Technical Operations or Chief Manufacturing Officer. CEO-level engagement is reserved for three categories: decisions with direct regulatory filing implications, CDMO relationship or contract terms, and capital allocation decisions for manufacturing capacity.
CEOs who receive a weekly CMC briefing from their technical operations leader, rather than participating in daily manufacturing stand-ups, preserve their ability to engage strategically without becoming an operational bottleneck.
CDMO Relationship Management as a CEO Time Investment
Many cell and gene therapy companies, particularly in the clinical stage, rely on CDMOs for viral vector manufacturing, fill-finish, or both. These relationships are often strategic, high-stakes, and difficult to replace quickly if they deteriorate.
CEO-level investment in the CDMO relationship is appropriate at several moments: initial contract negotiation and relationship establishment, when the program is entering a pivotal phase requiring reliable supply, and when problems arise that the operations team cannot resolve at the working level. In between those moments, the relationship should be owned by the VP of Technical Operations, with the CEO reachable as an escalation point.
Regulatory Time: FDA IND and BLA Engagement Across a Program’s Life
The CEO’s Role in Regulatory Strategy
A cell and gene therapy IND is more complex than a typical small-molecule IND. FDA reviewers in the Office of Tissues and Advanced Therapies (OTAT) are focused on a combination of clinical protocol design, patient selection criteria, manufacturing controls, and safety monitoring plans that reflect the unique characteristics of these modalities. The FDA’s guidance on gene therapy clinical trials outlines these expectations in detail. BLA reviews involve even deeper CMC scrutiny.
The CEO does not run the regulatory function. That is the job of the Chief Regulatory Officer or VP of Regulatory Affairs, often supported by experienced regulatory consultants. But the CEO shapes regulatory strategy in ways that matter: by deciding how aggressively to pursue Breakthrough Therapy Designation or Accelerated Approval pathways, by setting the tone for FDA interactions (constructive and transparent versus adversarial), and by allocating the resources required for a strong regulatory team.
For pharma CEO time management, the principle is the same in cell and gene therapy: protect time for the decisions only the CEO can make, and ensure the team has the authority and resources to handle the rest.
Pre-BLA and BLA Review Phase Time Demands
In the 12 to 18 months before a BLA submission, and throughout the FDA review period, cell and gene therapy CEOs face a spike in regulatory engagement demands. Type B and Type C meeting preparation, advisory committee preparation (if applicable), and labeling negotiations all require CEO awareness and sometimes direct participation.
The most effective CEOs in this phase establish a dedicated regulatory readiness rhythm: a monthly regulatory strategy review with the CRO and regulatory team, a quarterly update to the board on regulatory milestones, and a clear protocol for which FDA interactions require CEO-level briefing versus which can be handled by the regulatory team with a written summary to the CEO.
This structure prevents regulatory strategy from becoming a time sink while ensuring the CEO is never caught off-guard by a material regulatory development.
Hospital System Relationships and Patient Access Architecture
Why Hospital Relationships Require CEO Attention
Cell and gene therapies are administered in a small number of specialized treatment centers. CAR-T therapies, for example, are typically administered in academic medical centers and specialized cancer centers with the infrastructure to manage cell collection, REMS compliance, and severe toxicity management. Gene therapies for rare pediatric diseases may be administered at an even smaller number of centers nationwide.
This means the CEO’s relationship with the heads of those treatment centers is a genuine business development function, not a medical affairs formality. Decisions about which centers are authorized treatment centers, how the company supports center onboarding, and how the company responds when a center has a patient safety concern all have commercial and reputational implications that warrant CEO involvement.
Time allocation for hospital system relationship management should be planned, not reactive. Cell and gene therapy CEOs who embed a quarterly cadence of visits or calls with the five to ten treatment center medical directors most critical to their early commercial success create a relationship infrastructure that pays dividends when access, reimbursement, or safety questions arise.
Reimbursement Complexity as a Strategic Time Investment
Reimbursement for cell and gene therapies is one of the most complex and unsolved challenges in the industry. One-time therapies with multi-year clinical benefit are poorly accommodated by traditional annual benefit structures. Outcomes-based contracting, installment payment models, and manufacturer warranties are all being explored as solutions.
The CEO’s time investment in reimbursement strategy is warranted at the policy and payor relationship level. CEOs who engage directly with senior leaders at major commercial payors, CMS, and pharmacy benefit managers during the pre-launch and launch period establish relationships that matter when coverage decisions are made. This is a narrow but high-value use of CEO time.
For deeper context on protecting R&D oversight time while managing commercial demands, the same disciplined calendar architecture applies to the reimbursement engagement calendar.
Scientific Credibility: The CEO’s Most Differentiated Asset
What Scientific Credibility Means in Cell and Gene Therapy
In most industries, the CEO’s scientific or technical background is a background credential. In cell and gene therapy, it is often central to the CEO’s external effectiveness. Key opinion leaders, FDA reviewers, potential partners, and sophisticated investors all make judgments about the company based on how its CEO engages with the science.
A CEO who can discuss the vector design rationale for their gene therapy program, articulate the mechanism of cytokine release syndrome in the CAR-T context, or explain why their manufacturing process uses a specific transduction method will consistently perform better in investor meetings, KOL engagement, and FDA interactions than a CEO who defers all scientific questions to the CMO.
Protecting Time for Scientific Currency
Scientific credibility requires maintenance. Cell and gene therapy moves quickly. New clinical data from competitors, evolving FDA expectations in guidance documents, and new manufacturing technologies all require the CEO to invest time in staying current.
Practical approaches used by effective cell and gene therapy CEOs include: a dedicated two-hour block each week for reading key publications and reviewing competitor data; attendance at one or two major conferences per year with protected time for scientific sessions, not just investor meetings; and a monthly one-on-one with the Chief Scientific Officer or CMO specifically focused on the evolving scientific landscape rather than operational program updates.
These blocks are often the first to be sacrificed when the calendar fills with operational demands. Protecting them requires deliberate calendar management, ideally with an executive assistant who understands why these blocks exist and defends them accordingly.
Integrating the Four Domains: A Practical Time Allocation Framework
Quarterly Planning as the Foundation
Cell and gene therapy CEOs who manage their time most effectively treat quarterly planning as a serious process rather than a routine calendar exercise. Each quarter, they identify the two or three manufacturing, regulatory, commercial, or scientific milestones most critical to company value and allocate their personal time accordingly.
If the company is approaching an FDA Type B meeting, the regulatory domain gets elevated priority that quarter. If a CDMO contract is in renegotiation, CDMO relationship management gets elevated priority. If a pivotal clinical data readout is approaching, the investor relations and KOL relationship calendar gets elevated priority. This dynamic reallocation, planned at the quarterly level, prevents any single domain from chronically consuming CEO attention at the expense of the others.
Weekly Time Architecture
At the weekly level, effective cell and gene therapy CEOs protect two categories of time blocks: deep work blocks for complex analysis, writing, or scientific review, and relationship-focused blocks for external stakeholder engagement. Administrative work, including routine internal meetings, status reviews, and email management, is handled by the EA or delegated to direct reports wherever possible.
A common effective weekly architecture includes one morning per week reserved entirely for scientific and regulatory reading and writing, two to three afternoons per week reserved for external stakeholder calls and meetings, and the remaining time structured around leadership team meetings and internal decision-making.
Conclusion: Time Management as a Competitive Advantage
Time management for cell and gene therapy CEOs is ultimately about ensuring that the rarest resource in the company, the CEO’s focused attention, is consistently invested where it creates the most durable value. Manufacturing scale-up, FDA regulatory engagement, hospital system relationships, reimbursement strategy, and scientific credibility are all legitimate demands on that attention. The discipline lies in keeping all five domains properly served without allowing any one to crowd out the others.
Companies with effective CEO time architecture move faster through development, build stronger external relationships, and make better resource allocation decisions than companies where the CEO is perpetually reactive. In a field where the science is extraordinary but the execution challenges are equally formidable, that discipline can be the difference between a therapy that reaches patients and one that does not.
Related Reading
For further context, explore Time Management for Animal Health Pharma CEOs and Biologics CEO Time Management: Navigating Manufacturing Complexity.